Jason Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Jason heeft een totaal eigen vermogen van ¥6.3B en een totale schuld van ¥660.0M, wat de schuld-eigenvermogensverhouding op 10.5% brengt. De totale activa en totale passiva bedragen respectievelijk ¥11.7B en ¥5.4B. De EBIT Jason is ¥746.0M waardoor de rentedekking 149.2 is. Het heeft contanten en kortetermijnbeleggingen van ¥4.6B.

Belangrijke informatie

10.5%

Verhouding schuld/eigen vermogen

JP¥660.00m

Schuld

Rente dekkingsratio	149.2x
Contant	JP¥4.61b
Aandelen	JP¥6.29b
Totaal verplichtingen	JP¥5.37b
Totaal activa	JP¥11.66b

Recente financiële gezondheidsupdates

Does Jason (TYO:3080) Have A Healthy Balance Sheet?

May 06

Is Jason (TYO:3080) Using Too Much Debt?

Jan 25

Recent updates

Earnings Working Against Jason Co., Ltd.'s (TSE:3080) Share Price Following 26% Dive

Mar 01

Does Jason (TYO:3080) Have A Healthy Balance Sheet?

May 06

Do Jason's (TYO:3080) Earnings Warrant Your Attention?

Apr 21

The Attractive Combination That Could Earn Jason Co., Ltd. (TYO:3080) A Place In Your Dividend Portfolio

Apr 06

Declining Stock and Solid Fundamentals: Is The Market Wrong About Jason Co., Ltd. (TYO:3080)?

Mar 07

Jason Co., Ltd.'s (TYO:3080) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Dec 01

Shareholders Of Jason (TYO:3080) Must Be Happy With Their 132% Total Return

Nov 18

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( ¥8.0B ) 3080 } overtreffen de korte termijn passiva ( ¥4.3B ).

Langlopende schulden: De kortetermijnactiva 3080 ( ¥8.0B ) overtreffen de langetermijnschulden ( ¥1.1B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: 3080 heeft meer geld in kas dan de totale schuld.

Schuld verminderen: De schuld/eigen vermogen-ratio van 3080 is de afgelopen 5 jaar gedaald van 17.3% naar 10.5%.

Schuldendekking: De schuld van 3080 wordt goed gedekt door de operationele kasstroom ( 69.7% ).

Rentedekking: De rentebetalingen op de schuld van 3080 worden goed gedekt door EBIT ( 149.2 x dekking).

Jason Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Does Jason (TYO:3080) Have A Healthy Balance Sheet?

Is Jason (TYO:3080) Using Too Much Debt?

Recent updates

Jason Co., Ltd. to Report Q3, 2025 Results on Jan 14, 2025

Second quarter 2025 earnings released: EPS: JP¥11.08 (vs JP¥15.77 in 2Q 2024)

Jason Co., Ltd. to Report Q2, 2025 Results on Oct 15, 2024

First quarter 2025 earnings released: EPS: JP¥15.46 (vs JP¥17.95 in 1Q 2024)

Jason Co., Ltd. to Report Q1, 2025 Results on Jul 11, 2024

Full year 2024 earnings released: EPS: JP¥46.99 (vs JP¥46.75 in FY 2023)

Earnings Working Against Jason Co., Ltd.'s (TSE:3080) Share Price Following 26% Dive

Upcoming dividend of JP¥13.00 per share

Now 26% undervalued

Jason Co., Ltd. to Report Fiscal Year 2024 Results on Apr 12, 2024

Investor sentiment improves as stock rises 18%

Third quarter 2024 earnings released: EPS: JP¥8.43 (vs JP¥6.71 in 3Q 2023)

Investor sentiment improves as stock rises 21%

Jason Co., Ltd. to Report Q3, 2024 Results on Jan 11, 2024

Second quarter 2024 earnings released: EPS: JP¥15.77 (vs JP¥13.35 in 2Q 2023)

Now 21% undervalued

Jason Co., Ltd. to Report Q2, 2024 Results on Oct 12, 2023

First quarter 2024 earnings released: EPS: JP¥17.95 (vs JP¥16.70 in 1Q 2023)

Now 21% undervalued after recent price drop

Full year 2023 earnings released: EPS: JP¥46.75 (vs JP¥44.49 in FY 2022)

Full year 2023 earnings released: EPS: JP¥46.75 (vs JP¥44.49 in FY 2022)

Upcoming dividend of JP¥13.00 per share at 2.4% yield

Jason Co., Ltd. to Report Fiscal Year 2023 Results on Apr 13, 2023

Third quarter 2023 earnings released: EPS: JP¥6.71 (vs JP¥8.98 in 3Q 2022)

Investor sentiment improved over the past week

No independent directors

Jason Co., Ltd. to Report Q3, 2023 Results on Jan 12, 2023

Second quarter 2023 earnings released: EPS: JP¥13.35 (vs JP¥13.97 in 2Q 2022)

Jason Co., Ltd. to Report Q2, 2023 Results on Oct 13, 2022

First quarter 2023 earnings released: EPS: JP¥16.70 (vs JP¥14.91 in 1Q 2022)

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: JP¥44.49 (vs JP¥62.83 in FY 2021)

No independent directors

Jason Co., Ltd., Annual General Meeting, May 26, 2022

Full year 2022 earnings released: EPS: JP¥44.49 (vs JP¥62.83 in FY 2021)

Upcoming dividend of JP¥9.00 per share

Jason Co., Ltd. to Report Fiscal Year 2022 Results on Apr 13, 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: EPS JP¥13.97 (vs JP¥19.51 in 2Q 2021)

First quarter 2022 earnings released: EPS JP¥14.91 (vs JP¥25.68 in 1Q 2021)

Full year 2021 earnings released: EPS JP¥62.83 (vs JP¥38.40 in FY 2020)

Does Jason (TYO:3080) Have A Healthy Balance Sheet?

Do Jason's (TYO:3080) Earnings Warrant Your Attention?

Full year 2021 earnings released: EPS JP¥62.83 (vs JP¥38.40 in FY 2020)

The Attractive Combination That Could Earn Jason Co., Ltd. (TYO:3080) A Place In Your Dividend Portfolio

Declining Stock and Solid Fundamentals: Is The Market Wrong About Jason Co., Ltd. (TYO:3080)?

New 90-day low: JP¥608

Jason (TYO:3080) Could Be A Buy For Its Upcoming Dividend

Upcoming Dividend of JP¥9.00 Per Share

Jason (TYO:3080) Knows How To Allocate Capital Effectively

Jason Co., Ltd. to Report Fiscal Year 2021 Results on Apr 13, 2021

Is Jason (TYO:3080) Using Too Much Debt?

Third quarter 2021 earnings released: EPS JP¥9.44

If You Like EPS Growth Then Check Out Jason (TYO:3080) Before It's Too Late

Why Dividend Hunters Love Jason Co., Ltd. (TYO:3080)

Should You Rely On Jason's (TYO:3080) Earnings Growth?

Jason Co., Ltd.'s (TYO:3080) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

New 90-day low: JP¥667

Shareholders Of Jason (TYO:3080) Must Be Happy With Their 132% Total Return

First half earnings released

New 90-day high: JP¥901

Jason Co., Ltd. to Report Q2, 2021 Results on Oct 13, 2020

Analyse van de financiële positie

Schuld/ eigen vermogen geschiedenis en analyse

Balans

Ontdek gezonde bedrijven